Clinical Trial Update: BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating BAFFR-targeting CAR-T cells for relapsed or refractory B-cell acute lymphoblastic leukemia is currently active but not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BAFFR-targeting CAR-T cells

Snippet

Sponsor: PeproMene Bio, Inc. | Conditions: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING